News

DOD OTA Agreement Leveraged by Interagency for COVID-19 Rapid Response
April 10, 2020 — ABERDEEN PROVING GROUND, EDGEWOOD AREA, MD. – A Department of Defense (DOD) team led by the U.S. Air Force Agile Combat Support Program Executive Office Directorate (PEO ACS) leveraged an existing Other Transaction Authority (OTA) agreement within the Countering Weapons of Mass Destruction (CWMD) Consortium to award a Negatively Pressured Conex... MORE

DOD-Funded Diagnostic Test for COVID-19 Granted Emergency Use Authorization
March 31, 2020 — JPEO-CBRND’s industry partner BioFire Defense, LLC is producing COVID-19 tests to aid in pandemic response... MORE

Ology Bioservices, Inovio Partner To Manufacture COVID-19 DNA Vaccine With $11.9 Million Department of Defense Grant
March 24, 2020 — ALACHUA, Fla. & PLYMOUTH MEETING, Pa.--March 24, 2020--Ology Bioservices Inc., a biologics contract development and manufacturing organization (CDMO), and Inovio Pharmaceuticals Inc., (NASDAQ: INO) developing DNA medicines for infectious diseases and cancer, announced today that the Department of Defense (DOD) has awarded Ology Bioservices with a... MORE

Ology Bioservices, Vanderbilt University Medical Center to Develop, Manufacture Monoclonal Antibody for Treatment, Prevention of Infection With COVID-19 Virus for Department of Defense
March 23, 2020 — ALACHUA, Fla. – March 23, 2020 – The Department of Defense (DOD) awarded a contract valued at $14 million with Ology Bioservices Inc., a biologics contract development and manufacturing organization (CDMO), to develop and manufacture a monoclonal antibody for treatment and prevention of infection with the COVID-19 virus. This work is supported... MORE

DOD Leveraging Diagnostic Platform for COVID-19 Rapid Response
March 11, 2020 — JPEO-CBRND’s JPM CBRN Medical facilitated use of existing contract capabilities to address the global coronavirus threat... MORE

National Stock Numbers Assigned to Critical Medical Countermeasures for the Warfighter
February 11, 2020 — JPM CBRN Medical facilitated standardization and assignment of National Stock Numbers to promote Joint Force readiness... MORE

DEPARTMENT OF THE ARMY, THE SURGEON GENERAL (DA-TSG)-SPONSORED ASSAY SUPPORTS FIRST-EVER FDA-APPROVED EBOLA VACCINE IN U.S.
December 23, 2019 — JPM CBRN Medical’s filovirus program plays key role in Ebola vaccine’s FDA approval... MORE

Recombinant Botulinum Vaccine Generates Antibodies That Save Infants' Lives
December 2, 2019 — The JPM CBRN Medical approved an agreement on 14 January 2013 between Dynport Vaccine Company (DVC) and the California Department of Public Health (CDPH), authorizing DVC to provide the CDPH with the JPM CBRN Medical's recombinant Botulinum A/B (rBV A/B) vaccine, to generate hyperimmune plasma for the production of Human Botulism Immune Globulin... MORE

Collaboration Made NBCRV’s Sensor Suite Upgrade Possible
November 26, 2019 — Modified acquisition strategy leads to quick-turn modernization for U.S. Army... MORE

JPM CBRN Medical Teams With Janssen Vaccines & Prevention B.V. as Part of Larger Effort to Combat Ebola
November 1, 2019 — New Agreement focuses on a secondary vaccine used against potential Ebola outbreaks... MORE

News Search

News Archive - Search by Year and Month

2025 (7)
2024 (40)
2023 (36)
2022 (31)
2021 (37)
2020 (15)
2019 (11)
2018 (5)
2017 (9)
2016 (1)

JPEO-CBRND Press Kit

Download our press kit, which includes helpful documents to better understand our work, such as – Command Brief, Chemical Biological Defense Program's Enterprise strategy, the JPEO-CBRND's Capabilities Catalog, Leadership Biographies, COVID-19 fact sheets, and contracting overview documents.

JPEO-CBRND Public Affairs Office

The JPEO-CBRND Public Affairs Office coordinates and responds to all public affairs and media relations needs on behalf of the JPEO-CBRND. To request a speaker, subject matter expert, or for other interview or request for comment please email our Public Affairs Office email below.

The information contained in these articles has been reviewed and approved for public release.

The appearance of hyperlinks does not constitute endorsement by the JPEO-CBRND of non-U.S. government sites or the information, products, or services contained therein. Although the JPEO-CBRND may or may not use these sites as additional distribution channels for Department of Defense information, it does not exercise editorial control over all the information that you may find at these locations. Such hyperlinks are provided consistent with the stated purpose of this website.